Benjamin F. Edwards & Company Inc. Buys 4,334 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Benjamin F. Edwards & Company Inc. increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 540.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 5,136 shares of the medical equipment provider’s stock after acquiring an additional 4,334 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Intuitive Surgical were worth $1,733,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Intuitive Surgical by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock valued at $8,730,184,000 after acquiring an additional 196,316 shares during the period. Jennison Associates LLC boosted its holdings in shares of Intuitive Surgical by 6.4% during the 3rd quarter. Jennison Associates LLC now owns 4,585,190 shares of the medical equipment provider’s stock worth $1,340,205,000 after buying an additional 274,692 shares during the period. Fisher Asset Management LLC grew its stake in Intuitive Surgical by 2.0% in the 4th quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock valued at $1,516,222,000 after buying an additional 88,977 shares during the last quarter. Invesco Ltd. raised its holdings in Intuitive Surgical by 6.6% in the 3rd quarter. Invesco Ltd. now owns 3,750,490 shares of the medical equipment provider’s stock valued at $1,096,231,000 after acquiring an additional 232,205 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Intuitive Surgical by 3.4% during the third quarter. Northern Trust Corp now owns 3,514,421 shares of the medical equipment provider’s stock worth $1,027,230,000 after acquiring an additional 115,059 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Trading Up 1.0 %

NASDAQ ISRG opened at $381.36 on Monday. The firm has a market capitalization of $135.27 billion, a PE ratio of 68.84, a price-to-earnings-growth ratio of 4.93 and a beta of 1.39. The business’s 50-day moving average price is $385.40 and its two-hundred day moving average price is $350.34. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating the consensus estimate of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm’s revenue was up 11.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.00 earnings per share. As a group, analysts forecast that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

ISRG has been the subject of several recent research reports. Citigroup boosted their price target on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Robert W. Baird decreased their price target on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a research note on Friday, April 19th. Raymond James increased their target price on shares of Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. BTIG Research boosted their price target on Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research note on Friday, April 19th. Finally, Stifel Nicolaus lifted their price objective on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a report on Monday, April 8th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus price target of $396.17.

Insider Buying and Selling

In other news, EVP Robert Desantis sold 1,498 shares of the business’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $369.92, for a total value of $554,140.16. Following the transaction, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of Intuitive Surgical stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now directly owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Robert Desantis sold 1,498 shares of the business’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $369.92, for a total value of $554,140.16. Following the completion of the sale, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at $2,037,149.44. The disclosure for this sale can be found here. Insiders sold 226,928 shares of company stock valued at $87,833,828 over the last quarter. Insiders own 0.80% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.